M
Michael Kuettel
Researcher at Roswell Park Cancer Institute
Publications - 60
Citations - 4611
Michael Kuettel is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 24, co-authored 55 publications receiving 3854 citations. Previous affiliations of Michael Kuettel include Stanford University & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler,Emmanuel S. Antonarakis,Andrew J. Armstrong,Anthony V. D'Amico,Brian J. Davis,Tanya B. Dorff,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Michael E. Hurwitz,Joseph E. Ippolito,Christopher J. Kane,Michael Kuettel,Joshua M. Lang,Jesse K. McKenney,George J. Netto,David F. Penson,Elizabeth R. Plimack,Julio M. Pow-Sang,Thomas J. Pugh,Sylvia Richey,Mack Roach,Stan Rosenfeld,Edward M. Schaeffer,Ahmad Shabsigh,Eric J. Small,Daniel E. Spratt,Sandy Srinivas,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +32 more
TL;DR: The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer.
Journal ArticleDOI
Prostate cancer. Clinical practice guidelines in oncology.
James L. Mohler,Robert R. Bahnson,Barry Boston,J. Erik Busby,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Daniel J. George,Eric M. Horwitz,Robert P. Huben,Philip W. Kantoff,Mark H. Kawachi,Michael Kuettel,Paul H. Lange,Gary R. MacVicar,Elizabeth R. Plimack,Julio M. Pow-Sang,Mack Roach,Eric M. Rohren,Bruce J. Roth,Dennis C. Shrieve,Matthew R. Smith,Sandy Srinivas,Przemyslaw Twardowski,Patrick C. Walsh +24 more
Journal ArticleDOI
Prostate Cancer, Version 1.2016
James L. Mohler,Andrew J. Armstrong,Robert R. Bahnson,Anthony V. D'Amico,Brian J. Davis,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Michael E. Hurwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Joshua J. Meeks,David F. Penson,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Stan Rosenfeld,Edward M. Schaeffer,Ted A. Skolarus,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +31 more
TL;DR: This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Journal ArticleDOI
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology
James L. Mohler,Philip W. Kantoff,Andrew J. Armstrong,Robert R. Bahnson,Michael B. Cohen,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Timothy M. Kuzel,Richard T. Lee,Arnold W. Malcolm,David Miller,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Eric M. Rohren,Stan Rosenfeld,Edward M. Schaeffer,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Cy A. Stein,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Maria Ho +33 more
TL;DR: Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations.
Journal ArticleDOI
Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
James L. Mohler,Andrew J. Armstrong,Robert R. Bahnson,Barry Boston,J. Erik Busby,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Philip W. Kantoff,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Gary R. MacVicar,Arnold W. Malcolm,David Miller,Elizabeth R. Plimack,Julio M. Pow-Sang,Mack Roach,Eric M. Rohren,Stan Rosenfeld,Sandy Srinivas,Seth A. Strope,Jonathan D. Tward,Przemyslaw Twardowski,Patrick C. Walsh,Maria Ho,Dorothy A. Shead +29 more
TL;DR: Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation).